Drug General Information
Drug ID	D04MBS
Former ID	DIB005355
Drug Name	BMS-182657
Indication	Cardiovascular disorder [ICD10:I00-I99]		Terminated	[533583]
Company	Bristol-Myers Squibb Co
Structure		Download 2D MOL 3D MOL
Canonical SMILES	N1(C(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)S)CCc2c1cccc2)CC(=<br />O)O
CAS Number	CAS 160135-56-8
Target and Pathway
Target(s)	Neutral endopeptidase	Target Info	Modulator	[533583]
	Angiotensin-converting enzyme	Target Info	Modulator	[533583]
KEGG Pathway	Renin-angiotensin system
	Hematopoietic cell lineage
	Protein digestion and absorption
	Alzheimer's diseasehsa04614:Renin-angiotensin system
	Chagas disease (American trypanosomiasis)
	Hypertrophic cardiomyopathy (HCM)
NetPath Pathway	EGFR1 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway	Angiotensin Metabolism
Reactome	Metabolism of Angiotensinogen to AngiotensinsR-HSA-2022377:Metabolism of Angiotensinogen to Angiotensins
WikiPathways	Metabolism of Angiotensinogen to Angiotensins
	Primary Focal Segmental Glomerulosclerosis FSGS
	Alzheimers DiseaseWP554:ACE Inhibitor Pathway
References
Ref 533583	Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.
Ref 533583	Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.